Within cancer cells, the engagement of the cGAS/STING pathway is often linked to immune evasion and resistance to therapeutic agents, where varying levels of cGAS expression can affect how tumors respond to immune checkpoint inhibitors [36]. The gene discussed is STING1; the disease is cancer.